4Moving Biotech (4MB), a spin-off of 4P-Pharma developing the first potential disease-modifying drug (DMOAD) for knee osteoarthritis, announces that it has been awarded EUR  7.6 million in funding under the France 2030 plan to accelerate the clinical development of its lead candidate, 4P004, currently in a Phase 2a trial.

France 2030 is a highly selective and strategic initiative by the French government designed to fast-track the next generation of breakthrough innovations. 4MB's selection is a significant endorsement, granted through a rigorous, multi-stage evaluation process by leading scientific, clinical, and technological experts.

This recognition highlights the robust scientific foundations of the 4P004 program and its potential to deliver a truly transformative therapy for OA's unmet medical need and significant socio-economic impact with over 600 million people worldwide, including 10 million in France.

"We are honored by the renewed confidence through the France 2030 program. This highly competitive grant is a powerful validation of the scientific strengths of our 4P004 program and its potential to address one of the most pressing unmet medical needs," said Revital Rattenbach, Co-founder and President of 4MB.

This additional funding will accelerate the 4P004 INFLAM MOTION Phase 2a clinical study, a GLP-1 analog designed to harness anti-inflammatory, analgesic, anti-catabolic, and anabolic effects across all joint tissues. The trial's primary objective is to evaluate the efficacy of a single intra-articular injection of 4P004 in reducing knee pain while also assessing structural improvements via contrast-enhanced MRI and exploring novel biomarkers for disease progression and delayed need for total knee replacement.

"4MB gains extended momentum through The France 2030 grant marks an important milestone in the 4MB roadmap. With our phase 2a already initiated, this funding strengthens the value of our work, from early-stage discovery to clinical stage, and highlights the need to bring transformative therapies for patients suffering from OA," said Luc Boblet, CEO of 4MB.

With the support of the France 2030 initiative, 4MB is fully equipped to deliver clinical proof-of-concept on time, as a critical inflection point that will unlock the next stage of development and reveal the full potential of 4P004 as a first-in-class DMOAD, creating significant attractiveness for future partnerships.